Effects of enoxaparin on myeloperoxidase release during hemodialysis

Hemodialysis International

Volumn 18, Issue 4, 2014, Pages 819-824

  Gozdzikiewicz, Joanna ^a   Borawski, Jacek ^a   Koc Zorawska, Ewa ^a   Mysliwiec, Michal ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Anticoagulation; Dialyzer; Enoxaparin; Hemodialysis; Heparin; Myeloperoxidase

Indexed keywords

ENOXAPARIN; HEPARIN; MYELOPEROXIDASE; POLYACRYLONITRILE; ANTICOAGULANT AGENT; PEROXIDASE;

ADULT; ANTICOAGULATION; ARTICLE; ARTIFICIAL KIDNEY; CLINICAL ARTICLE; DIALYSIS MEMBRANE; ENZYME BLOOD LEVEL; FEMALE; HEMODIALYSIS; HUMAN; MALE; NEUTROPHIL COUNT; BLOOD; DRUG EFFECTS; ENZYME ACTIVATION; MIDDLE AGED; PROCEDURES; RENAL REPLACEMENT THERAPY;

ANTICOAGULANTS; ENOXAPARIN; ENZYME ACTIVATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PEROXIDASE; RENAL DIALYSIS;

EID: 84926192771     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/hdi.12177     Document Type: Article

References (21)

1. 1 Lau D, Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther. 2006; 111:16-26.
2. 2 Arnhold J, Flemmig J. Human myeloperoxidase in innate and acquired immunity. Arch Biochem Biophys. 2010; 500:92-106.
3. 3 Daphna EM, Michaela S, Eynat P, Irit A, Rimon S. Association of myeloperoxidase with heparin: Oxidative inactivation of proteins on the surface of endothelial cells by the bound enzyme. Mol Cell Biochem. 1998; 183:55-61.
4. 4 Baldus S, Rudolph V, Roiss M, etal. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation. 2006; 113:1871-1878.
5. 5 Rudolph TK, Rudolph V, Witte A, etal. Liberation of vessel adherent myeloperoxidase by enoxaparin improves endothelial function. Int J Cardiol. 2010; 140:42-47.
6. 6 Suranyi M, Chow JS. Review: Anticoagulation for haemodialysis. Nephrology (Carlton). 2010; 15:386-392.
7. 7 Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351:1296-1305.
8. 8 Naumnik B, Pawlak K, Myśliwiec M. Unfractionated heparin but not enoxaparin causes delayed plasma PAI-1 depletion in hemodialysis patients: A prospective study. Clin Appl Thromb Hemost. 2009; 15:84-91.
9. 9 Naumnik B, Borawski J, Pawlak K, Mysliwiec M. Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-beta1 during haemodialysis: A cross-over study. Nephrol Dial Transplant. 2007; 22:1690-1696.
10. 10 Borawski J, Dubowski M, Pawlak K, Mysliwiec M. Sulodexide induces hepatocyte growth factor release in humans. Eur J Pharmacol. 2007; 558:167-171.
11. 11 Borawski J, Naumnik B, Myśliwiec M. Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: Role of heparin. Kidney Int. 2003; 64:2229-2237.
12. 12 Baldus S, Eiserich JP, Mani A, etal. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest. 2001; 108:1759-1770.
13. 13 de la Rebière G, Franck T, Deby-Dupont G, etal. Effects of unfractionated and fractionated heparins on myeloperoxidase activity and interactions with endothelial cells: Possible effects on the pathophysiology of equine laminitis. Vet J. 2008; 178:62-69.
14. 14 Li S, Chen X, Wu T, etal. Role of heparin on serum VEGF levels and local VEGF contents in reducing the severity of experimental severe acute pancreatitis in rats. Scand J Gastroenterol. 2012; 47:237-244.
15. 15 Zhao D, Ding R, Mao Y, Wang L, Zhang X, Ji Z. Heparin rescues sepsis-associated acute lung injury and lethality through the suppression of inflammatory responses. Inflammation. 2012; 35:1825-1832.
16. 16 Mu E, Ding R, An X, Li X, Chen S, Ma X. Heparin attenuates lipopolysaccharide-induced acute lung injury by inhibiting nitric oxide synthase and TGF-beta/Smad signaling pathway. Thromb Res. 2012; 129:479-485.
17. 17 Gedik HS, Korkmaz K, Erdem H, Karakilic E, Lafci G, Ankarali H. Protective effect of heparin in the end organ ischemia/reperfusion injury of the lungs and heart. J Cardiothorac Surg. 2012; 15:123.
18. 18 Rudolph TK, Schaper N, Klinke A, etal. Liberation of vessel-adherent myeloperoxidase reflects plaque burden in patients with stable coronary artery disease. Atherosclerosis. 2013; 231:354-358.
19. 19 Elsayed E, Becker RC. The impact of heparin compounds on cellular inflammatory responses: A construct for future investigation and pharmaceutical development. J Thromb Thrombolysis. 2003; 15:11-18.
20. 20 Rudolph V, Rudolph TK, Schopfer FJ, etal. Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. J Pharmacol Exp Ther. 2008; 327:324-331.
21. 21 Borawski J. Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: The underestimated modifying effects of heparin. Am J Kidney Dis. 2006; 47:37-41.